FOXM1 Is Strongly Associated with Cell Proliferation and Is Not Influenced by Metabolic Syndrome in GEP-NETS Abstract #1810

Introduction: Gastro-entero-pancreatic neuroendocrine tumors(GEP-NETs) and metabolic syndrome(MS) are both increasing exponentially. MS has been associated with several non NET cancers.
Aim(s): To evaluate the influence of MS and their individual criteria in GEP-NETs expression of cell proliferation and inflammation molecular markers.
Materials and methods: IHC studies for Ki-67, FOXM1, IGF1R and IL-6 were performed in GEP-NETs paraffin-embedded tissue(n=39) and its expression was quantified by computerized image analysis.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Ana Paula Santos

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1675 Abdominal Obesity, Fasting Glucose and Metabolic Syndrome Are Risk Factors for Well Differentiated Digestive Neuroendocrine Tumors
Introduction: Digestive NETs(DNETs)`s incidence has increased last 40 years. Visceral obesity and metabolic syndrome (MetSyn) were recently reported to be associated with several cancers, although not so far with DNET.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr. Ana Paula Santos
#2770 Evaluation of Early Predictors of Metabolic Syndrome in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Introduction: Metabolic syndrome and obesity (MetS) are supposed to have a role in cancer but data analysing their association with GEP-NET are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD Roberta Modica
#1530 Bizarre Neuroendocrine Tumour Presentations
Introduction: Herein we present two cases of neuroendocrine tumours (NET)with atypical presentations.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Clinical cases/reports
Presenting Author: Carolina Palmela
#2874 Role of FOXM1 in Aggressive Pancreatic / Pulmonary Neuroendocrine Carcinomas and Anti-Tumor Effect of the FOXM1 Inhibitor Thiostrepton
Introduction: DNA-targeting agents are the main treatment of aggressive pulmonary and pancreatic neuroendocrine carcinomas (NEC). FOXM1 is a transcription factor controlling cell proliferation and DNA repair pathways, playing therefore an important role in tumor progression and chemoresistance.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Jerome Cros
#895 Determination of a Prognostic Classification System in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (PNETs)
Introduction: There is no clinical prognostic risk stratification tool available for metastatic grade 1 and 2 PNETs, which are a heterogeneous group.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: MD Julen Fernández Plana